

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7140698

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
KATANA PHARMACEUTICALS, INC.	01/20/2022
RECEIVING PARTY DATA	
Name:	ELGAN PHARMA LTD
Street Address:	NEW GENERATION TECHNOLOGIES NGT3, 13 WADI EL-HAJ STREET
City:	NAZARETH
State/Country:	ISRAEL
Postal Code:	1711102
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16378521
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(703) 859-9634
Email:	martin@ipatent.co.il
Correspondent Name:	MARTIN MOYNIHAN D/B/A PRTSI, INC.
Address Line 1:	CUSTOMER NUMBER 67801
Address Line 2:	232 NW 42ND TER
Address Line 4:	PLANTATION, FLORIDA 33317
ATTORNEY DOCKET NUMBER:	91146
NAME OF SUBMITTER:	MARTIN D. MOYNIHAN
SIGNATURE:	/Martin D. Moynihan/
DATE SIGNED:	01/26/2022
Total Attachments: 1	
source=91146 Executed Assignment from Katana Pharmaceuticals Inc to Elgan Pharma Ltd#page1.tif	

ASSIGNMENT

For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned (hereinafter called the "Assignor"):

Katana Pharmaceuticals, Inc.
380 Hamilton Avenue, Box 952
Palo Alto, CA 94302

hereby sell(s), assign(s) and transfer(s), or hereby confirms the ownership of the below named Assignee(s) if previously assigned thereto, to:

Elgan Pharma Ltd
New Generation Technologies NGT3, 13 Wadi El-Haj Street
1711102 Nazareth
Israel

(hereinafter called the "Assignee"), its successors, assigns, nominees or other legal representatives, the undersigned's entire rights, title and interest in and to the invention titled:

OXYTOCIN COMPOSITIONS AND METHODS OF USE

described and claimed in the following Patent Application:

US Patent Application No. 16/378,521,
filed on April 8, 2019,
and identified as Attorney Docket No. 91146

and in and to said Patent Application, and all original and reissued Patents granted therefore, and all divisions and continuations thereof, any corresponding PCT Patent Application and the National Phases thereof, including the right to apply and obtain Patents in all other countries, the right to claim priority under International Conventions, and the Letters Patent which may be granted thereon:


covenant that the undersigned have (has) the full right to convey the entire interest therein assigned;

authorize(s) and request(s) the Registrar of Patents, and any Official of any country whose duty it is to issue Patents on applications as aforesaid, to issue the said Letters Patent to the said Assignee;

and agree(s) to sign all lawful papers, make all rightful oaths, do all lawful acts requisite for such Patent Applications, and do everything possible to aid said Assignee to apply for, obtain and enforce Patent protection for said invention.

ASSIGNOR

Katana Pharmaceuticals, Inc.

Signature : 


Name : Dean Carson

Capacity : CEO

Date : 1/20/2022

ASSIGNEE

Elgan Pharma Ltd

Signature : 

Name : Michal Otshansky

Capacity : CEO

Date : 24 Jan 2022

PATENT